Damora Therapeutics completes redomestication from Delaware to Cayman Islands

Damora Therapeutics, Inc.

Redomestication effective July 16, 2026; each common share converted 1:1 into ordinary shares of Cayman company.
New CUSIP G2646Y104; ordinary shares continue trading on Nasdaq under symbol DMRA as of July 20, 2026.
No change in business, management, obligations, assets, or liabilities; company remains a U.S. corporation for tax purposes.
Stockholders approved the redomestication at a special meeting on February 9, 2026.
Company also entered into indemnification agreements with directors and executive officers.

item 1.01 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.